Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 3:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo/Saline solution Clear all
Completed Not applicable Interventional Results available

Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial

NCT01597557
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Magnesium Sulfate, Placebo
Drug · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

NCT01984983
View directory record Official record
Conditions
Venezuelan Equine Encephalitis Virus Infection
Interventions
Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo
Biological · Other
Lead sponsor
Ichor Medical Systems Incorporated
Industry
Eligibility
18 Years to 49 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of CSX-1004

NCT06005402
View directory record Official record
Conditions
Opioid Overdose, Opioid Use Disorder
Interventions
CSX-1004, Placebo
Biological
Lead sponsor
Cessation Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 14, 2026, 3:09 AM EDT
Terminated Phase 4 Interventional Results available

Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure

NCT02899156
View directory record Official record
Conditions
Hypoactive Delirium
Interventions
Flumazenil, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

NCT02411539
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

NCT02920528
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 14, 2026, 3:09 AM EDT
Withdrawn Phase 2 Interventional

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00715364
View directory record Official record
Conditions
Stroke
Interventions
NTx™-265: rhCG, then rEPO, Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 14, 2026, 3:09 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Rezafungin

NCT04117607
View directory record Official record
Conditions
Fungal Infection
Interventions
Placebo, Rezafungin
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 14, 2026, 3:09 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244
View directory record Official record
Conditions
Healthy
Interventions
Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix
Biological
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 49 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
119
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 14, 2026, 3:09 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

NCT04540900
View directory record Official record
Conditions
Skin Roughness, Wrinkle, Fine Lines, Skin Thickness
Interventions
KB301, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
4
States / cities
Campbell, California • Newport Beach, California • Rancho Santa Margarita, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

NCT00538434
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years to 18 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 14, 2026, 3:09 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents

NCT02679274
View directory record Official record
Conditions
Aging
Interventions
Placebo, Testosterone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Galveston, Texas • Texas City, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Sep 14, 2026, 3:09 AM EDT
Recruiting Phase 2 Interventional

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

NCT06812390
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Albumin infusion (25% albumin), Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Anahita Rabiee MD MHS
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Airway Alkalinization and Nasal Colonization

NCT03078088
View directory record Official record
Conditions
Healthy Subjects, Cystic Fibrosis
Interventions
Tham, Saline
Drug
Lead sponsor
Lakshmi Durairaj
Other
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

NCT00379236
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
EUFLEXXA™, placebo
Device
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2011 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 3 Interventional Results available

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

NCT00059332
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Magnesium Sulfate, Normal Saline
Drug
Lead sponsor
Jeffrey L. Saver
Other
Eligibility
40 Years to 95 Years
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Intramuscular (IM) Oxytocin on Pupil Diameter and Heart Rate Variability (HRV)

NCT04105998
View directory record Official record
Conditions
Chronic Pain Due to Injury
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 66 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 2 Interventional Results available

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

NCT04832971
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ARO-ANG3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 2 Interventional Results available

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

NCT02437487
View directory record Official record
Conditions
Clostridium Difficile
Interventions
SER-109, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Oceanside, California • Sacramento, California • Ventura, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

NCT05196919
View directory record Official record
Conditions
Facet Joint Pain, Back Pain, Inflammation
Interventions
XT-150, Placebo
Biological
Lead sponsor
Xalud Therapeutics, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Napa, California • Santa Monica, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Not applicable Interventional Results available

Lidocaine For Neuroprotection During Cardiac Surgery

NCT00938964
View directory record Official record
Conditions
Cognitive Decline
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 3 Interventional Results available

Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection

NCT01472965
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection
Interventions
ethanol, heparin-saline placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 25 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 14, 2026, 3:09 AM EDT
Enrolling by invitation Phase 2 Interventional

Interleukin-15 to Promote Post-ART Control of HIV

NCT07145164
View directory record Official record
Conditions
HIV
Interventions
N-803, Saline placebo
Drug
Lead sponsor
Michael Peluso, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 14, 2026, 3:09 AM EDT
Completed Phase 3 Interventional

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

NCT03414268
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
Micronized dHACM, Saline Injection
Other · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 79 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Tucson, Arizona • Carlsbad, California • Carmichael, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Sep 14, 2026, 3:09 AM EDT